Adults who are smokers are less likely to be prescribed a GLP-1 than nonsmokers, even though smokers are more likely to be eligible to receive a medication, according to findings published in Diabetes ...

AbbVie has launched its Produodopa therapy for Parkinson’s disease onto the market in the EU, becoming the first and only 24-hour levodopa-based subcutaneous ...